$6.61
+17%OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
IMDX • NASDAQ
| Insight Molecular Diagnostics Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||
-50.2M | -60.7M | -27.8M | -72.9M | -64.1M | -29.9M | -22.4M | -15.8M | -19.4M | -11.2M | -8.7M | -5M | -3.5M | |
2.2M | 1.6M | 1.7M | 5.2M | 4.2M | 394K | 351K | 559K | 580K | 387K | 283K | 281K | 277K | |
0.0 | 0.0 | 0.0 | 0.0 | -9.3M | -1.3M | 483K | 956K | 4.4M | 0.0 | 65K | 0.0 | -326K | |
2.2M | 1.9M | 6.6M | 10M | 6.8M | 5.1M | 3M | 1.5M | 1.6M | 922K | 1.8M | 318K | 326K | |
20.9M | 37.8M | 174K | 14M | 26.2M | -2.2M | 437K | 118K | 83K | 1.7M | 18K | 291K | 326K | |
2.7M | -1.3M | -4M | -1.9M | 149K | 2M | -1.6M | 993K | -686K | 2.3M | 2.3M | 3.2M | 2.2M | |
-22.2M | -20.7M | -23.3M | -45.6M | -35.9M | -26M | -19.7M | -11.6M | -13.4M | -7.5M | -4.2M | -1.2M | -710K | |
INVESTING ACTIVITIES | |||||||||||||
-3.2M | -516K | -281K | -4.3M | -2.2M | -1.2M | -918K | -31K | -91K | -106K | -500K | -9K | -25K | |
(0.0) | (0.0) | (0.0) | (0.0) | -11.7M | -10.5M | -11.2M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -11.2M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 367K | 0.0 | 0.0 | 0.0 | 11.2M | 0.0 | 934K | 0.0 | 815K | 1.3M | 0.0 | |
0.0 | 4K | -1M | 0.0 | 0.0 | -7K | -252K | -240K | 934K | -75K | 815K | 1.3M | 0.0 | |
-3.2M | -512K | -932K | -4.3M | -14M | -11.7M | -12.4M | -31K | (843K) | -181K | (315K) | (1.3M) | -25K | |
FINANCING ACTIVITIES | |||||||||||||
28.7M | 27.8M | 13.8M | 32.8M | 77.7M | 20.8M | 48.9M | 13.6M | 0.0 | 10.6M | 11.6M | 0.0 | 0.0 | |
-510K | -201K | -117K | -1.4M | -1.5M | 695K | 1.4M | -1.2M | 1.6M | -114K | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -96K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | -239K | -14K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-74K | -1.8M | -427K | -483K | 2.2M | 1.3M | 0.0 | -201K | 8.4M | -555K | 4K | 0.0 | 0.0 | |
28.1M | 20.4M | 12.2M | 35.8M | 78.4M | 22.8M | 47.9M | 12.1M | 10M | 9.9M | 11.7M | 0.0 | 0.0 | |
CASH FLOW SUMMARY | |||||||||||||
973K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
3.7M | -796K | -12.1M | -14.1M | 28.5M | -14.9M | 15.7M | 434K | -2.6M | 2.2M | 7.7M | 156K | -735K | |
8.6M | 11.1M | 23.2M | 37.3M | 8.8M | 23.8M | 8M | 7.6M | 10.2M | 8M | 257K | 101K | 836K | |
12.3M | 10.3M | 11.1M | 23.2M | 37.3M | 8.8M | 23.8M | 8M | 7.6M | 10.2M | 8M | 257K | 101K | |
-25.4M | -21.2M | -23.6M | -49.9M | -38.2M | -27.2M | -20.6M | -11.7M | -13.5M | -7.6M | -4.7M | -1.2M | -735K |
IMDX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K/A 8-K/A 2026 (Amended) N/A | May 13, 2026 | February 20, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 11, 2026 | February 11, 2026 | 2026 |
Continue your IMDX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.